Beyond the Approval: Operationalizing Zongertinib for HER2-Mutant Lung Cancer

Zongertinib (Hernexeos; Boehringer Ingelheim) is more than another targeted agent entering a crowded non-small cell lung cancer (NSCLC) landscape. Its arrival underscores a workflow challenge familiar to oncology pharmacists: a therapy cannot deliver precision care unless the right alteration is identified, the prescription is operationalized correctly, and toxicities are recognized early.

In February 2026, the FDA expanded zongertinib’s accelerated approval to adults with unresectable or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) tyrosine kinase domain (TKD)–activating mutations detected by an FDA-authorized test, removing the prior-treatment requirement.¹ The broader indication makes HER2 testing and oral anticancer medication management relevant from the first treatment decision.

A Selective TKI With Frontline Activity

Zongertinib is an oral, irreversible TKI designed to inhibit mutant HER2 while sparing wild-type EGFR. That selectivity is clinically important because earlier pan-HER inhibitors have been limited by EGFR-associated diarrhea and rash.

In the phase 1a/1b, single-arm Beamion LUNG-1 trial (NCT04886804), 74 previously untreated patients who received zongertinib 120 mg once daily had a confirmed objective response rate of 76%; median duration of response was 15.2 months, and median progression-free survival was 14.4 months.² In a separate cohort of 30 patients with active brain metastases, the confirmed intracranial response rate was 47%.² These findings are encouraging, particularly in a molecular subgroup with frequent central nervous system involvement.

The activity was also consistent with earlier results in previously treated disease. Among 75 patients with HER2 TKD mutations who had not received a prior HER2-directed TKI, the confirmed objective response rate was 71%, the median duration of response was 14.1 months, and the median progression-free survival was 12.4 months.³

Biomarker Precision Comes First

Eligibility hinges on a HER2 TKD-activating mutation—not HER2 protein overexpression or amplification alone. Pharmacists participating in molecular tumor boards, treatment-plan review, or prior authorization can help verify that the pathology or next-generation sequencing report identifies an eligible mutation and that testing satisfies labeling requirements.¹

This distinction also matters during patient counseling. “HER2-positive” can mean different biological findings across tumor types; explaining that zongertinib targets a specific genomic driver may reduce confusion with HER2-directed therapies used in breast or gastric cancers.

Turning an Oral Prescription Into Safe Therapy

The labeled dose is weight-based: 120 mg once daily for patients weighing less than 90 kg and 180 mg once daily for those weighing 90 kg or more. Tablets may be taken with or without food and should be swallowed whole. A missed dose may be taken within 12 hours; after that window, it should be skipped. Patients should not redose after vomiting.⁴

Medication reconciliation deserves particular attention. Strong CYP3A inducers should be avoided when possible, and zongertinib can increase exposure to breast cancer resistance protein substrates, requiring a review of concomitant therapies and monitoring.⁴

Monitoring Beyond Diarrhea and Rash

Common adverse reactions include diarrhea, rash, hepatotoxicity, fatigue, nausea, musculoskeletal pain, and upper respiratory tract infection.⁴ Pharmacists can establish early antidiarrheal plans and reinforce prompt reporting, but surveillance must extend further. The prescribing information calls for liver function tests at baseline, every 2 weeks for the first 12 weeks, and monthly thereafter as clinically indicated. Left ventricular ejection fraction should be assessed before treatment and periodically, and new cough, dyspnea, or fever warrants evaluation for interstitial lung disease/pneumonitis.⁴

Zongertinib’s response data are compelling, but accelerated approval remains based on response rate and durability rather than randomized survival evidence.¹ Ongoing confirmatory testing will define its long-term place. Meanwhile, pharmacists can make its current use more precise by closing the gaps between biomarker identification, access, adherence, and toxicity management.

REFERENCES

1. FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer. FDA. News Release. Published February 26, 2026. Accessed August 5, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-unresectable-or-metastatic-non-squamous-non-small-cell

2. Heymach JV, Yamamoto N, Girard N, et al. First-line zongertinib in advanced HER2-mutant non-small-cell lung cancer. N Engl J Med. 2026;394(17):1675-1684. doi:10.1056/NEJMoa2516969

3. Heymach JV, Ruiter G, Ahn MJ, et al. Zongertinib in previously treated HER2-mutant non-small-cell lung cancer. N Engl J Med. 2025;392(23):2321-2333. doi:10.1056/NEJMoa2503704

4. Hernexeos (zongertinib) tablets, for oral use. Prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc; revised February 2026. Accessed August 5, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219042s001lbl.pdf